Pentti Põder

6.4k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Pentti Põder is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Pentti Põder has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 2 papers in Surgery and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Pentti Põder's work include Heart Failure Treatment and Management (12 papers), Cardiac pacing and defibrillation studies (7 papers) and Cardiovascular Function and Risk Factors (5 papers). Pentti Põder is often cited by papers focused on Heart Failure Treatment and Management (12 papers), Cardiac pacing and defibrillation studies (7 papers) and Cardiovascular Function and Risk Factors (5 papers). Pentti Põder collaborates with scholars based in Finland, Estonia and France. Pentti Põder's co-authors include Matti Kivikko, Alexandre Mebazaa, Alain Cohen‐Solal, Markku S. Nieminen, Milton Packer, Stuart Pocock, Franz X. Kleber, Roopal Thakkar, Robert J. Padley and Lasse Lehtonen and has published in prestigious journals such as JAMA, European Heart Journal and Critical Care.

In The Last Decade

Pentti Põder

14 papers receiving 1.0k citations

Hit Papers

Levosimendan vs Dobutamine for Patients With Acute Decomp... 2007 2026 2013 2019 2007 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure
    2007 645 citations Alexandre Mebazaa, Markku S. Nieminen et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pentti Põder Finland 11 906 297 222 187 154 14 1.1k
Francesco Clemenza Italy 18 780 0.9× 285 1.0× 407 1.8× 103 0.6× 273 1.8× 65 1.2k
Georgios Sidéris France 16 538 0.6× 162 0.5× 325 1.5× 254 1.4× 121 0.8× 47 898
Claudio Picariello Italy 19 659 0.7× 120 0.4× 194 0.9× 122 0.7× 79 0.5× 68 973
Salah E. Altarabsheh United States 17 625 0.7× 179 0.6× 597 2.7× 60 0.3× 185 1.2× 63 923
Don Chomsky United States 15 902 1.0× 240 0.8× 302 1.4× 99 0.5× 288 1.9× 23 1.2k
David Parra United States 16 375 0.4× 114 0.4× 192 0.9× 121 0.6× 142 0.9× 62 779
K. Swedberg Sweden 8 890 1.0× 133 0.4× 216 1.0× 57 0.3× 497 3.2× 12 1.1k
Douglas S. Schulman United States 20 860 0.9× 96 0.3× 350 1.6× 81 0.4× 348 2.3× 38 1.2k
V-P Harjola Finland 2 684 0.8× 227 0.8× 183 0.8× 134 0.7× 121 0.8× 3 784
Bengt Redfors Sweden 17 316 0.3× 135 0.5× 445 2.0× 280 1.5× 145 0.9× 36 1.2k

Countries citing papers authored by Pentti Põder

Since Specialization
Citations

This map shows the geographic impact of Pentti Põder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pentti Põder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pentti Põder more than expected).

Fields of papers citing papers by Pentti Põder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pentti Põder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pentti Põder. The network helps show where Pentti Põder may publish in the future.

Co-authorship network of co-authors of Pentti Põder

This figure shows the co-authorship network connecting the top 25 collaborators of Pentti Põder. A scholar is included among the top collaborators of Pentti Põder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pentti Põder. Pentti Põder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Ambrosio, Giuseppe, Lars H. Lund, Stefano Coiro, et al.. (2021). Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. European Journal of Internal Medicine. 89. 65–75. 23 indexed citations
2.
Vinereanu, Dragoş, Д. А. Напалков, Jutta Bergler‐Klein, et al.. (2020). Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study). Open Heart. 7(1). e001202–e001202. 6 indexed citations
3.
Nikolaou, Maria, John Parissis, Mehmet Birhan Yılmaz, et al.. (2012). Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. European Heart Journal. 34(10). 742–749. 201 indexed citations
4.
Nieminen, Markku S., John G.F. Cleland, Jaan Eha, et al.. (2008). Oral Levosimendan in Patients with Severe Chronic Heart Failure—The PERSIST Study. European Journal of Heart Failure. 10(12). 1246–1254. 43 indexed citations
5.
Mebazaa, Alexandre, Markku S. Nieminen, Milton Packer, et al.. (2007). Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure. JAMA. 297(17). 1883–1883. 645 indexed citations breakdown →
6.
Lehtonen, Lasse & Pentti Põder. (2006). The utility of levosimendan in the treatment of heart failure. Annals of Medicine. 39(1). 2–17. 28 indexed citations
7.
Põder, Pentti, et al.. (2004). Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study. The Journal of Clinical Pharmacology. 44(10). 1143–1150. 30 indexed citations
8.
Mebazaa, Alexandre, Alain Cohen‐Solal, F. X. Kleber, et al.. (2004). Study design of a mortality trial with intravenous levosimendan - the SURVIVE study - in patients with acutely decompensated heart failure. Journal of Cardiac Failure. 10(4). S81–S81. 10 indexed citations
9.
Mebazaa, Alexandre, Alain Cohen‐Solal, Franz X. Kleber, et al.. (2004). Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. Critical Care. 8(Suppl 1). P87–P87. 8 indexed citations
10.
Põder, Pentti, et al.. (2003). Pharmacodynamic Interactions of Levosimendan and Felodipine in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy. 17(5-6). 451–458. 14 indexed citations
11.
Põder, Pentti, et al.. (2003). Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.. PubMed. 41(8). 365–73. 15 indexed citations
12.
13.
Moiseyev, V.S., Pentti Põder, Л. Б. Лазебник, et al.. (2002). RUSSLAN STUDY INVESTIGATORS. SAFETY AND EFFICACY OF A NOVEL CALCIUM SENSITIZER, LEVOSIMENDAN, IN PATIENTS WITH LEFT VENTRICULAR FAILURE DUE TO AN ACUTE MYOCARDIAL INFARCTION. A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (RUSSLAN). 23. 1422–1432. 39 indexed citations
14.
Moiseyev, V.S., et al.. (1999). Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarct. Journal of Cardiac Failure. 5(3). 43–43. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Clemenza Breakdown of academic impact, for papers by Georgios Sidéris Breakdown of academic impact, for papers by Claudio Picariello Breakdown of academic impact, for papers by Salah E. Altarabsheh Breakdown of academic impact, for papers by Don Chomsky Breakdown of academic impact, for papers by David Parra Breakdown of academic impact, for papers by K. Swedberg Breakdown of academic impact, for papers by Douglas S. Schulman Breakdown of academic impact, for papers by V-P Harjola Breakdown of academic impact, for papers by Bengt Redfors
Rankless by CCL
2026